-
Nov 14, 2024 | 
law360.com | Jacqueline R. Berman |Michele L. Buenafe |Kathleen M. Sanzo
By Jacqueline Berman, Michele Buenafe and Kathleen Sanzo ( November 14, 2024, 6:41 PM EST) -- The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, has prompted many in the life sciences industry to question how this political shift may affect the regulation of drugs, devices and other life sciences products by the U.S. Food and Drug Administraiton and related regulators....
-
Nov 14, 2024 | 
law360.co.uk | Jacqueline R. Berman |Michele L. Buenafe |Kathleen M. Sanzo
By Jacqueline Berman, Michele Buenafe and Kathleen Sanzo ( November 14, 2024, 6:41 PM EST) -- The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, has prompted many in the life sciences industry to question how this political shift may affect the regulation of drugs, devices and other life sciences products by the U.S. Food and Drug Administraiton and related regulators....
-
Nov 12, 2024 | 
jdsupra.com | Jacqueline R. Berman |Michele L. Buenafe |Rebecca Dandeker
The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, has prompted many in the life sciences industry to question how this political shift may impact the regulation of drugs, devices, and other life sciences products by FDA and related regulators.
-
Nov 8, 2024 | 
morganlewis.com | Jacqueline R. Berman |Michele L. Buenafe |Rebecca Dandeker |Dennis Gucciardo
The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, has prompted many in the life sciences industry to question how this political shift may impact the regulation of drugs, devices, and other life sciences products by FDA and related regulators.
-
Sep 24, 2024 | 
morganlewis.com | Michael Abernathy |Stephen Altieri |Louis W. Beardell |Jacqueline R. Berman |Olga Berson |Christopher J. Betti | +23 more
NEW YORK, September 24, 2024: Morgan Lewis has received 13 practice rankings and 27 individual lawyer recognitions in the 2024 edition of Legal Media Group’s (LMG) LMG Life Sciences guide, an annual guide that honors law firms and lawyers for outstanding work in life sciences.
-
Jul 9, 2024 | 
jdsupra.com | Michael Abernathy |Jacqueline R. Berman |Christopher J. Betti
The US Supreme Court’s decision in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce, which overrules the longstanding Chevron doctrine that required federal courts to defer to administrative agencies’ interpretations of ambiguous or broad statutes, represents a fundamental change in administrative law that will have a substantial impact on all regulated industries.
-
May 23, 2024 | 
jdsupra.com | Jacqueline R. Berman |Michele L. Buenafe |Alexandre Gapihan
On May 21, 2024, The Drug Enforcement Administration (DEA) issued a notice of proposed rulemaking in the Federal Register (FR) to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). This announcement comes nearly a year after the US Department of Health and Human Services (HHS) August 29, 2023 letter to the DEA recommending that marijuana be rescheduled.
-
May 23, 2024 | 
morganlewis.com | Kathleen M. Sanzo |Michele L. Buenafe |Jacqueline R. Berman |Alexandre Gapihan
On May 21, 2024, The Drug Enforcement Administration (DEA) issued a notice of proposed rulemaking in the Federal Register (FR) to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). This announcement comes nearly a year after the US Department of Health and Human Services (HHS) August 29, 2023 letter to the DEA recommending that marijuana be rescheduled.
-
Apr 18, 2024 | 
jdsupra.com | Jacqueline R. Berman
The development of psychedelic drugs for medicinal uses has substantially expanded since 2020, as evidenced by an exponential growth in Drug Enforcement Administration (DEA) production quotas for both psilocybin and psilocin. In 2024, these quotas grew to 20,000 g and 24,000 g, respectively, from just 30 g and 50 g in 2020.
-
Apr 17, 2024 | 
morganlewis.com | Jacqueline R. Berman
The development of psychedelic drugs for medicinal uses has substantially expanded since 2020, as evidenced by an exponential growth in Drug Enforcement Administration (DEA) production quotas for both psilocybin and psilocin. In 2024, these quotas grew to 20,000 g and 24,000 g, respectively, from just 30 g and 50 g in 2020.
